Kestra Medical Technologies Earnings Call Highlights Rapid Growth

Kestra Medical Technologies Ltd. ((KMTS)) has held its Q4 earnings call. Read on for the main highlights of the call.

TipRanks Welcomes a New ETF – NYSE:RANK

• TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
• RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Kestra Medical Technologies’ latest earnings call struck an upbeat tone, underscored by rapid revenue growth, expanding margins, and strong clinical validation for its wearable cardiac defibrillator platform. Management balanced this optimism with a candid discussion of ongoing losses and heavy operating investments, arguing that today’s spending is building a foundation for durable long‑term growth in a still‑underpenetrated market.

Explosive Revenue Growth Signals Strong Market Demand

Kestra reported Q4 revenue of $28.6 million, up 66% year over year, highlighting powerful momentum in its core business. For fiscal 2026, revenue climbed to $95 million, a 59% increase versus FY2025, reinforcing that demand for the company’s ASSURE wearable cardioverter defibrillator is scaling quickly across its target patient base.

Prescription Surge and Commercial Footprint Expansion

Accepted prescriptions topped 6,300 in Q4, with volumes rising roughly 63% year over year according to management. The company broadened its commercial reach, growing new prescribers by 55%, ordering facilities by 65%, and expanding sales territories from around 80 to approximately 130 over the fiscal year.

Gross Margin Expansion and Strengthening Unit Economics

Profitability metrics improved markedly, with Q4 gross margin reaching 54.8% versus 44.3% in the prior‑year period, an increase of more than 10 percentage points. Full‑year gross margin rose to 51.4%, up about 11 points year over year, and Kestra highlighted 10 consecutive quarters of sequential margin expansion as it targets 70%‑plus margins in the coming years.

Clinical Evidence Underscores Product Differentiation

The ACE‑PAS study, described as the largest real‑world wearable cardioverter defibrillator study, enrolled more than 21,000 patients and showed low false alarm rates, strong wear compliance, and 100% successful conversion of dangerous arrhythmias. The study’s citation in a Heart Rhythm journal paper endorsing WCD consideration bolsters Kestra’s clinical credibility and may influence future treatment guidelines.

Product Innovation and Strategic Partnerships

Kestra rolled out an enhanced detection algorithm in April, now shipping to all patients, which is expected to further reduce false alarms and improve user experience. Management also highlighted steady progress in its collaboration with BioBeat and noted that additional pipeline projects are aimed at deepening differentiation for the ASSURE platform in an evolving cardiac monitoring and protection market.

Fortified Balance Sheet and Ample Liquidity

The company closed the quarter with $262 million in cash, cash equivalents, and investments, providing a robust financial cushion. A new $200 million term loan facility with Pharmakon, of which $75 million was funded at close, lifts total liquidity to around $357 million and offers non‑dilutive capital for potential M&A and continued strategic investment.

Adjusted EBITDA Loss Highlights Profitability Challenges

Despite strong growth, profitability remains pressured, with adjusted EBITDA loss widening to $26.7 million in Q4 from a $20.3 million loss a year ago. Management acknowledged the ongoing negative adjusted results but framed them as the consequence of aggressive commercial and operational expansion required to capture a large unmet market opportunity.

Higher Operating Expenses Reflect Deliberate Investment

Operating expenses excluding nonrecurring items and stock‑based compensation rose to $44.7 million in Q4, up from $29.7 million in the prior‑year period. Kestra attributed the increase to sizable spending on commercial infrastructure and revenue cycle management, which have lifted SG&A and near‑term cash burn while aiming to drive future scale and efficiency.

Net Loss Narrows But Cash Burn Persists

GAAP net loss improved to $38.8 million in Q4 compared with $51.1 million in the year‑ago quarter, signaling some progress even as bottom‑line results remain negative. Operating cash flow stayed in the red, with $18.7 million of cash used in operating activities, though this was better than the $24.1 million used in the prior‑year period.

Conversion Variability and Near‑Term Execution Risks

The company’s conversion rate ended the year at roughly 46%, only modestly higher than the prior year, and dipped slightly in Q4 as prescriptions surged late in the quarter. Management noted that new sales representatives require about six months to ramp, introducing short‑term phasing and cadence risks as the organization absorbs rapid hiring and territory expansion.

Underpenetrated Market and Competitive Uncertainty

Kestra reiterated that wearable cardiac defibrillators remain underutilized, estimating that six out of seven indicated patients are currently unprotected, which presents both significant upside and execution risk. Competitive dynamics and regulatory developments, including activity affecting rivals and new product rollouts, add uncertainty to the landscape even as Kestra seeks to solidify its position.

Guidance Points to Sustained Growth and Rising Efficiency

For fiscal 2027, Kestra guided revenue to $137 million, a 44% increase over FY2026, driven by prescription growth, deeper penetration of existing accounts, and new account activation. Management also projected continued gross‑margin expansion from the current 54.8% level toward a long‑term goal above 70%, better collections through RCM and AI tools, operating leverage as territories scale to about 170, and declining operating cash burn supported by the company’s sizable liquidity.

Kestra’s earnings call painted a picture of a high‑growth medtech player investing heavily to secure leadership in a still‑nascent market for wearable cardiac defibrillators. Investors will be watching closely to see whether management can translate rapid top‑line growth, margin gains, and strong clinical data into sustainable profitability while navigating competitive and regulatory crosscurrents.